About this trial

The purpose of this study is to determine the natural history of the hereditary forms of nephrolithiasis and chronic kidney disease (CKD), primary hyperoxaluria (PH), cystinuria, Dent disease and adenine phosphoribosyltransferase deficiency (APRTd) and acquired enteric hyperoxaluria (EH). The investigator will measure blood and urinary markers of inflammation and determine relationship to the disease course. Cross-comparisons among the disorders will allow us to better evaluate mechanisms of renal dysfunction in these disorders.

Eligibility criteria

Qualifiers

Diagnosis of primary hyperoxaluria

Diagnosis of enteric hyperoxaluria

Diagnosis of Dent Disease

Diagnosis of Cystinuria

Disqualifiers

Prior renal failure

History of liver and/or kidney transplant.

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

220 Participants
are grouped into 7 trial groups

7

Trial groups

See each trial group below.

Locations

11
Canada
Hosptial of Sick ChildrenM5G 1X8, TorontoOntario, Canada
Iceland
Landspitali Universtiy Hospital Reykjavik Iceland
Israel
Shaare Zedek Medica Center Jerusalem Israel
United States
Alabama
University of Alabama @ Birmingham35294, Birmingham United States

Sponsors and collaborators

Mayo Clinic

Lead sponsor